DNL126
PreclinicalSmall molecule
DNL126 is one of 26 small molecule programs targeting Mucopolysaccharidosis. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Mucopolysaccharidosis
#DrugCompanyPhaseTrials
1Rituxan
RocheApproved
Trexall
Alnylam PharmaceuticalsApproved
Neoral
NovartisApproved
Immunoglobulin
SanofiApproved
Imuran
LLegacy Health System
Approved
BMN 333
BioMarin PharmaceuticalPhase 3
ELAPRASE
TakedaApproved
ELAPRASE
TakedaPhase 3
Humira
CCelltrion
Phase 2
Genotropin
EMD SeronoPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DNL126. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- DDenali Therapeutics Inc.